絞り込み

17048

広告

スターを付ける スターを付ける     (15view , 0users)

Full Text Sources

Medical

Research Materials

Nivolumab plus ipilimumab or nivolumab alone resulted in longer progression-free and overall survival than ipilimumab alone in a trial involving patients with advanced melanoma. We now report 5-year outcomes in the trial.
PMID: 31562797 [PubMed - as supplied by publisher]
印刷用ページを開く Endnote用テキストダウンロード